Ribose (Furanose)

Ribose (Furanose)

SCHEMBL4576206

NC(=O)c1nc(N)c[nH]1.OC[C@H]1OC(O)[C@H](O)[C@@H]1O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
ALDH1A1 P00352 4/20 0.42
MTOR P42345 2/20 0.42
THRB P10828 1/20 0.42
MDM2 Q00987 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
POLB P06746 1/20 0.42
TP53 P04637 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 1/20 0.41
THPO P40225 2/20 0.40
PMP22 Q01453 2/20 0.40
HTT P42858 2/20 0.40
BLM P54132 2/20 0.40
TSHR P16473 2/20 0.40
UMPS P11172 1/20 0.40
GMNN O75496 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL9616546 0.89 LMNA (0.42) LMNASMN1; SMN2ALDH1A1MTORTHRB
SCHEMBL5369246 0.82 P2RY14 (0.39) ALDH1A1ADORA1
Ribose (Furanose) SCHEMBL5798254 0.80 KDM4E (0.42) LMNASMN1; SMN2ALDH1A1MTORTHRB
SCHEMBL27614390 0.78 UMPS (0.48) LMNASMN1; SMN2ALDH1A1TP53KDM4E
SCHEMBL8561 0.77
Ribose (Furanose) SCHEMBL142622 0.77 LMNA (0.49) LMNASMN1; SMN2ALDH1A1MTORTHRB
Ribose (Furanose) SCHEMBL8833 0.77 LMNA (0.49) LMNASMN1; SMN2ALDH1A1MTORTHRB
Ribose (Furanose) SCHEMBL2325834 0.77 LMNA (0.49) LMNASMN1; SMN2ALDH1A1MTORTHRB
Ribose (Furanose) SCHEMBL3341287 0.77 LMNA (0.49) LMNASMN1; SMN2ALDH1A1MTORTHRB
Ribose (Furanose) SCHEMBL3673370 0.76 KDM4E (0.44) LMNASMN1; SMN2ALDH1A1MTORPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
EP-1853539-A2 HONOKIOL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Arbiser, Jack (US) 2007-11-14 EP disclosed
WO-2006107451-A2 HONOKIOL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS UNIV EMORY (US) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders CCNK, CDK3, CCNO LMNA 921/4885SMN1; SMN2 1535/4885ALDH1A1 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.